factor VIII gene therapy valoctocogene roxaparvovec
Selected indexed studies
- Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. (N Engl J Med, 2022) [PMID:35294811]
- Gene therapy for hemophilia. (Hematology Am Soc Hematol Educ Program, 2022) [PMID:36485127]
- Roctavian gene therapy for hemophilia A. (Blood Adv, 2024) [PMID:38991118]
_Worker-drafted node — pending editorial review._
Connections
factor VIII gene therapy valoctocogene roxaparvovec is a side effect of
Sources
- Gene therapy for hemophilia. (2022) pubmed
- Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. (2022) pubmed
- Roctavian gene therapy for hemophilia A. (2024) pubmed
- Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. (2024) pubmed
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. (2023) pubmed
- Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B. (2024) pubmed
- Valoctocogene Roxaparvovec: First Approval. (2022) pubmed
- Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A. (2024) pubmed
- Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. (2025) pubmed
- Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. (2024) pubmed